11th Annual California Cancer Consortium Conference
“Recent Advances and New Directions in Cancer Therapy”
August 7 – 9, 2015, Westin Pasadena, Pasadena, California

Educational Steering Committee & Conference Chairs
Dr. Primo Lara, Jr.  UC Davis Comprehensive Cancer Center
Dr. Edward Newman  City of Hope Comprehensive Cancer Center
Dr. Robert Morgan  City of Hope Comprehensive Cancer Center

Presented by the California Cancer Consortium
University of California Davis Comprehensive Cancer Center, Sacramento, CA
City of Hope Comprehensive Cancer Center, Duarte, CA
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
University of Pittsburgh Cancer Institute/UPMC, Pittsburgh, PA
Barbara Ann Karmanos Comprehensive Cancer Center (Wayne State University), Detroit, MI
Penn State Hershey Cancer Institute (Penn State University), Hershey, PA

Sponsored by The Medical Educator Consortium
THE MEDICAL EDUCATOR CONSORTIUM

COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.
- Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this educational activity for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
THE MEDICAL EDUCATOR CONSORTIUM

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is AMA PRA Category 1 Credits™, and has been taken within the appropriate time frames.
DISTINGUISH FACULTY

Edwin Alvarez, MD
Assistant Professor, Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
UC Davis Comprehensive Cancer Center, Sacramento, CA

Afsaneh Barzi, MD, PhD
Assistant Professor of Medical Oncology, Department of Medicine, Division of Oncology
USC Norris Comprehensive Cancer Center, Los Angeles, CA

Chandra Belani, MD
Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA
Deputy Director and Associate Director of Clinical Research, Penn State Hershey Cancer Institute, Hershey, PA

Jan H. Beumer, PharmD, PhD
Assistant Professor, Pharmaceutical Sciences
University of Pittsburgh, Cancer Institute, Pittsburgh, PA

Suzette Blanchard, PhD
Associate Research Professor, Division of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA

Preet Chaudhary, MD, PhD
Chief, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases
Professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research
Program Director, USC/Norris Blood and Marrow Transplant Program
Co-leader, Molecular Genetics Program, Norris Comprehensive Cancer Center
Keck School of Medicine of USC, University of Southern California, Los Angeles, CA

Helen Chew, MD
Professor of Medicine, Division of Hematology/Oncology
UC Davis Comprehensive Cancer Center, Sacramento, CA

Warren Chow, MD
Department of Medical Oncology & Therapeutics Research
Department of Molecular Pharmacology
City of Hope, Duarte, CA

Mihaela Cristea, MD
Associate Clinical Professor, Medical Oncology, Lung Cancer and Thoracic Oncology Program
Gynecologic Oncology, Gynecological Oncology/Peritoneal Malignancy Program
City of Hope, Duarte, CA

Savita Dandapani, MD
Assistant Professor, Radiation Oncology
City of Hope, Duarte, CA

Tanya Dorff, MD
Assistant Professor
University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA

Anthony El-Khoueiry, MD
Assistant Professor, University of Southern California Keck School of Medicine
Norris Comprehensive Cancer Center, Los Angeles, CA
THE MEDICAL EDUCATOR CONSORTIUM

Marwan Fakih, MD
Interim Chair and Professor, Medical Oncology and Therapeutics Research
Section Head, GI Medical Oncology
Co-Director, GI Cancers Program
City of Hope Comprehensive Cancer Center, Duarte, CA

Shirish Gadgeel, MD
Leader, Thoracic Oncology Multidisciplinary Team, Karmanos Cancer Center, Detroit, MI
Professor, Wayne State University School of Medicine, Detroit, MI

Agustin Garcia, MD, MMM
Associate Professor of Medicine and Obstetrics & Gynecology
Director Clinical Research, Women’s Cancer Program
USC Norris Comprehensive Cancer Center, Los Angeles, CA

Barbara J. Gitlitz, MD
Associate Professor of Medicine, USC Keck School of Medicine, Los Angeles, CA

Susan Groshen, PhD
Professor of Research, Department of Preventive Medicine, University of Southern California, Los Angeles, CA

Elisabeth I. Heath, MD, FACP
Hartmann Endowed Chair for Prostate Cancer Research,
Professor of Oncology and Medicine,
Director, Prostate Cancer Research Karmanos Cancer Institute Wayne State University School of Medicine, Detroit, MI

Syma Iqbal, MD, FACP
Associate Professor of Clinical Medicine
Program Director, Medical Oncology Fellowship
USC/Keck School of Medicine, Norris Cancer Center
Division of Medical Oncology, Los Angeles, CA

Brian Jonas, MD, PhD
Assistant Professor of Medicine, Division of Hematology/Oncology,
UC Davis Comprehensive Cancer Center, Sacramento, CA

Michael Khan, PhD
Professor of Biochemistry and Molecular Biology
Provost's Professor of Medicine and Pharmacy
Co-Chair, GI Oncology Program
USC Norris Comprehensive Cancer Center, Los Angeles, CA
USC Center for Molecular Pathways and Drug Discovery, Los Angeles, CA

Karen Kelly, MD
Professor of Medicine
Associate Director for Clinical Research
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon
Endowed Chair in Cancer Clinical Research
UC Davis Comprehensive Cancer Center, Sacramento, CA

Kevin Kelly, MD, PhD
Associate Professor of Clinical Medicine
Assistant Medical Director of Clinical Investigations Support Office, Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California, Los Angeles, CA

Edward Kim, MD, PhD
Assistant Professor Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center, Sacramento, CA
Marianna Koczywas, MD  
Clinical Professor  
City of Hope  
Department of Medical Oncology and  
Therapeutic Research  
Thoracic Oncology and Lung Cancer Program

Shivaani Kummar, MD  
Professor, Department of Medicine  
Director, Phase I Clinical Research Program  
Stanford University School of Medicine, Stanford, CA

Primo N. Lara, Jr., MD  
Professor of Medicine, UC Davis School of Medicine  
Associate Director for Translational Research, UC Davis Comprehensive Cancer Center, Sacramento, CA

Heinz-Josef Lenz, MD, PhD  
Professor of Medicine and Preventive Medicine/Section Head of GI Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA  
Associate Director for Clinical Research, USC Norris Comprehensive Cancer Center, Los Angeles, CA

Jeffrey Longmate, PhD  
Professor and Director Division of Biostatistics, Department of Information Sciences Beckman Research Institute/City of Hope Comprehensive Cancer Center, Duarte, CA

Philip C. Mack, PhD  
Associate Adjunct Professor  
UC Davis Cancer Center, Sacramento, CA

Robert Morgan, MD  
Professor of Medicine, Department of Medical Oncology and Therapeutics Research  
Co-director, Gynecological Cancers Program  
City of Hope Comprehensive Cancer Center, Duarte, CA

Edward Newman, PhD  
Associate Professor, Molecular Pharmacology  
Co-director, Analytical Pharmacology Core Facility  
City of Hope Comprehensive Cancer Center, Duarte, CA

Philip Philip, MD  
Professor of Medicine, Wayne State University School of Medicine, Detroit, MI  
Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI

Leslie Popplewell, MD, FACP  
Hematology and Hematopoietic Cell Transplantation  
City of Hope Medical Center, Duarte, CA

David Quinn, MBBS, PhD  
Associate Professor and Head Section of GU Medical Oncology, USC Keck School of Medicine, Los Angeles, CA; Leader Developmental Therapeutics Program, USC Norris Comprehensive Cancer Center, Los Angeles, CA

Karen L. Reckamp, MD, MS  
Associate Professor of Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA

Jonathan W. Riess, MD, MS  
Assistant Professor of Medicine, Division of Hematology and Oncology,  
UC Davis Comprehensive Cancer Center, Sacramento, CA
THE MEDICAL EDUCATOR CONSORTIUM

Steven Rosen, MD  
Provost & Chief Scientific Officer  
Director, Comprehensive Cancer Center and Beckman Research Institute  
Irell & Manella Cancer Center Director's Distinguished Chair  
City of Hope, Duarte, CA

Sarmad Sadeghi, MD, PhD  
Assistant Professor, University of Southern California, Division of Oncology  
Norris Comprehensive Cancer Center, Los Angeles, CA

Thomas Semrad, MD, MAS, FACP  
Assistant Professor of Medicine Division of Hematology and Oncology,  
UC Davis Comprehensive Cancer Center, Sacramento, CA

Tanya Siddiqi, MD  
Assistant Professor Department of Hematology & Hematopoietic Cell Transplantation,  
City of Hope National Medical Center, Duarte, CA

George Somlo, MD  
Professor, Department of Medical Oncology and Therapeutics Research  
City of Hope Comprehensive Cancer Center, Duarte, CA

CA Stein, MD, PhD  
Arthur and Rosalie Kaplan Professor and Chair  
Department of Medical Oncology and Experimental Therapeutics  
City of Hope Medical Center, Duarte, CA

Timothy Synold, PharmD  
Co-director Analytical Pharmacology Core Facility  
Associate Professor, Molecular Pharmacology  
City of Hope Comprehensive Cancer Center, Duarte, CA

Ahmad Tarhini, MD, PhD  
Associate Professor, Dept. of Medicine, Hematology-Oncology  
Clinical and Translational Science Institute, University of Pittsburgh School of Medicine  
Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute  
UPMC Cancer Pavilion, Pittsburgh, PA

Joseph Tuscano, MD  
Professor of Medicine Division of Hematology and Oncology, UC Davis School of Medicine/  
University of California Davis Comprehensive Cancer Center, Sacramento, CA

Przemyslaw Twardowski, MD  
Clinical Professor of Medical Oncology, City of Hope Medical Center, Duarte, CA

Ulka Vaishampayan, MD  
Associate Professor of Medicine, Wayne State University School of Medicine  
Barbara Ann Karmanos Cancer Institute, Detroit, MI

Hong Zheng, MD, Ph.D  
Assistant Professor of Medicine Division of Hematology/Oncology, Penn State Hershey Cancer Institute  
Penn State University College of Medicine, Hershey, PA
THE MEDICAL EDUCATOR CONSORTIUM

CONFERENCE AGENDA

Friday, August 7, 2015

11:00AM  Registration Opens & Visit Exhibits

12:00-1 PM  Lunch Symposia (non CME)

1:00 PM  Welcome and Introductions
Primo Lara (UCD), Edward Newman (COH), Robert Morgan (COH)

1:15  SESSION 1: LUNG CANCER
Chair: Karen Reckamp (COH)

1:20-1:35  Squamous Cell Lung Cancer: Emerging Developments
David Gandara (UCD)

1:35-1:40  Question and Answer

1:40-1:55  Non-Squamous Non-Small Cell Lung Cancer: Beyond EGFR and ALK
Chandra Belani (PSU)

1:55-2:00  Question and Answer

2:00-2:15  What’s New in Small Cell Lung Cancer Therapeutics?
Shirish Gadgeel (WSU)

2:15-2:20  Question and Answer

2:20  SESSION 2: GENITOURINARY CANCERS (I)
Chair: Primo Lara (UCD)

2:25-2:40  Drug Development in Castration Resistant Prostate Cancer
Przemyslaw Twardowski (COH)

2:40-2:45  Question and Answer

2:45-3:00  New Developments in Urothelial Cancer Therapeutics
Sarmad Sadeghi (USC)

3:00-3:05  Question and Answer

3:05-3:20  Refreshment Break, Visit Exhibits

3:20  SESSION 3: GASTROINTESTINAL CANCERS (I)
Chair: Heinz Josef Lenz (USC)

3:20-3:35  Hepatocellular and Hepatobiliary Cancers
Anthony El-Khoueiry (USC)

3:35-3:40  Question and Answer

3:40-3:55  Adenocarcinoma of the Pancreas: New Developments
Edward Kim (UCD)

3:55-4:00  Question and Answer
4:00  SESSION 4: NOVEL TARGETS IN ONCOLOGY DRUG DEVELOPMENT (I)
     Chair: Barbara Gitlitz (USC)

4:00-4:15  Anti-mitotic Agents: Eribulin, Tubulin Inhibitors
          David Quinn (USC)

4:15-4:30  Fibroblast Growth Factor Inhibitors
          Thomas Semrad (UCD)

4:30-4:45  Next-Generation EGFR Inhibitors
          Jonathan Riess (UCD)

4:45-5:00  Next-Generation Angiogenesis Inhibitors
          Tanya Dorff (USC)

5:00-5:30  PANEL DISCUSSION: Better Targets or Just Newer?
          (Session Faculty)

5:30-6:30  Welcome Reception, Visit Exhibits
          Appetizers, wine, cheese

Saturday, August 8, 2015

7:00 AM  REGISTRATION & Visit Exhibits

7:00-8:00  Breakfast Symposium (non CME)

8:00  Welcome and Introductions
      Primo Lara, Edward Newman, Robert Morgan

8:05  SESSION 5: INNOVATIVE CLINICAL TRIAL DESIGNS FOR THE GENOMIC ERA
      Chairs: Jeff Longmate (COH), Susan Groshen (USC)

8:10-8:20  Novel Dose Escalation Strategies
           Jeff Longmate (COH)

8:20-8:30  Biostatistical Considerations for Phase II Trials
           Susan Groshen (USC)

8:30-8:40  Basket vs Umbrella Clinical Trials
           Suzette Blanchard (COH)

8:40-9:05  PANEL DISCUSSION: Optimal Clinical Trial Designs
           Session Faculty

9:05  SESSION 6: HEMATOLOGIC MALIGNANCIES (I)
      Chair: Joseph Tuscano (UCD)

9:10-9:25  Novel Agents in Development for Acute Leukemia
           Brian Jonas (UCD)

9:25-9:30  Question and Answer

9:30-9:45  Chronic B- and T-cell Leukemias: New Developments
           Kevin Kelly (USC)

9:45-9:50  Question and Answer
SESSION 7: GENITOURINARY CANCER (II)
Chair: Ulka Vaishampayan (WSU)

9:55-10:10 Renal Cell Cancer: New Agents in Development
Tanya Dorff (USC)

10:10-10:15 Question and Answer

10:15-10:30 Prostate Cancer: New Therapeutics for the Pre-Castrate Resistant Prostate Cancer Patient
Elisabeth Heath (WSU)

10:30-10:35 Question and Answer

SESSION 8: GASTROINTESTINAL CANCER (II)
Chairs: Thomas Semrad (UCD), Afsaneh Barzi (USC)

10:55-11:10 Emerging Developments in Metastatic Colorectal Cancer
Syma Iqbal (USC)

11:10-11:15 Question and Answer

11:15-11:30 State of the Art Management of Upper GI Tract Cancers (Gastric, GE Junction, Neuroendocrine Pancreatic Tumors)
Philip Philip (WSU)

SESSION 9: CANCER IMMUNOTHERAPY
Chair: Leslie Popplewell (COH)

11:40-11:55 Checkpoint Inhibitors: Current Status and Future Directions
Karen Kelly (UCD)

11:55-12:00 Question and Answer

12:00-12:15 Cancer Vaccines and T-Cell Based Approaches
Mihaela Cristea (COH)

12:15-12:20 Question and Answer

12:20-12:35 Antibody-Drug Conjugates
Tanya Siddiqi (COH)

12:35-12:40 Question and Answer

SESSION 10: HEMATOLOGIC MALIGNANCIES (II)
Chair: Leslie Popplewell (COH)

1:40-1:55 New Molecular Agents for Malignant Lymphoma
Steven Rosen (COH)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:55</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Multiple Myeloma: Latest and Greatest</td>
<td>Joseph Tuscano (UCD)</td>
</tr>
<tr>
<td>2:15</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>2:20</td>
<td>Follicular Lymphoma: Latest and Greatest</td>
<td>Hong Zheng (PSU)</td>
</tr>
<tr>
<td>2:35</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>2:40</td>
<td>SESSION 11: GYNECOLOGIC CANCER</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Robert Morgan (COH)</td>
<td></td>
</tr>
<tr>
<td>2:45</td>
<td>Refractory Ovarian Cancer: New Approaches</td>
<td>Agustin Garcia (USC)</td>
</tr>
<tr>
<td>3:00</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>3:05</td>
<td>Endometrial and Cervix Cancers</td>
<td>Edwin Alvarez, MD (USC)</td>
</tr>
<tr>
<td>3:20</td>
<td>Question and Answer</td>
<td></td>
</tr>
<tr>
<td>3:25</td>
<td>SESSION 12: BEST OF THE CALIFORNIA CANCER CONSORTIUM (II)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Robert Morgan (COH)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fellow-led Presentation of CCC Research</td>
<td></td>
</tr>
<tr>
<td>3:40</td>
<td>Refreshment Break, Visit Exhibits</td>
<td></td>
</tr>
<tr>
<td>3:55</td>
<td>SESSION 13: CLINICAL AND MOLECULAR PHARMACOLOGY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Edward Newman (COH), Tim Synold (COH)</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>PK/PD Modeling</td>
<td>Jan Beumer (UOP)</td>
</tr>
<tr>
<td>4:10</td>
<td>Optimizing Preclinical Cancer Models</td>
<td>Philip Mack (UCD)</td>
</tr>
<tr>
<td>4:20</td>
<td>Specimen Collection and Molecular Phenotyping for Clinical Trials, Circulating DNA</td>
<td>Shivaani Kummar (Stanford)</td>
</tr>
<tr>
<td>4:30</td>
<td>Adaptive control: The Original Personalized Medicine</td>
<td>Tim Synold (COH)</td>
</tr>
<tr>
<td>4:40</td>
<td>PANEL DISCUSSION: Biomarker and PK Correlative Studies in the Era of Reduced Funding</td>
<td>Session Faculty</td>
</tr>
<tr>
<td>5:10</td>
<td>Adjourn for Day</td>
<td></td>
</tr>
</tbody>
</table>
Sunday, August 9, 2015

7:00 AM Registration, Visit Exhibits

7:00-8:00 Breakfast Symposium (non cme)

8:00 Welcome and Introductions
Primo Lara, Edward Newman, Robert Morgan

8:05 SESSION 15: NOVEL TARGETS IN ONCOLOGY DRUG DEVELOPMENT (II)
Chair: Edward Newman (COH)

8:10-8:25 Oligonucleotide Therapeutics
Cy Stein (COH)

8:25-8:40 WNT signalling
Michael Khan (USC)

8:40-8:55 Targeting DNA Repair: ADR Inhibitors (Radiosensitzers)
Savita Dandapani (COH)

8:55-9:10 Signal Transduction Inhibitors (MET, MEK, AKT, etc)
Marwan Fakih (COH)

9:10-9:25 Question and Answer (session faculty)

9:25 SESSION 16: NEW DEVELOPMENTS IN HEMATOLOGY/ONCOLOGY
Chair: Primo Lara (UCD)

9:30-9:45 Malignant Melanoma: Latest and Greatest
Ahmad Tarhini (UOP)

9:45-9:50 Question and Answer

9:50-10:05 Targeted Drug Development for KSHV-Associated Malignancies
Preet Chaudhary (USC)

10:05-10:10 Question and Answer

10:10-10:25 Refreshment Break, Visit Exhibits

10:25-10:40 Soft Tissue Sarcoma: Latest and Greatest
Warren Chow, (COH)

10:40-10:45 Question and Answer

10:45 SESSION 17: BREAST CANCER
Co-chairs: George Somlo, Helen Chew

10:50-11:05 Emerging Treatments for Metastatic Triple Negative Breast Cancer
George Somlo (COH)

11:05-11:10 Question and Answer

11:10-11:25 HER2 Positive Breast Cancer: New Standards of Care
Helen Chew (UCD)
THE MEDICAL EDUCATOR CONSORTIUM

11:25-11:30    Question and Answer

11:30-11:55    SESSION 18: PANEL DISCUSSION:
               New Directions of the NCI in the Team Science Era
               Faculty: Primo Lara, Edward Newman, Heinz Josef Lenz,
               Chandra Belani, Robert Morgan

11:55-12:00    Closing Remarks and Adjourn